Skip to main content
. 2022 Apr 17;14(8):2028. doi: 10.3390/cancers14082028
NENs neuroendocrine neoplasms
GEP-NETs gastroenteropancreatic neuroendocrine tumors
IARC-WHO International Agency for Research on Cancer—World Health Organization
NECs neuroendocrine cancers
MiNEN mixed neuroendocrine-nonneuroendocrine neoplasms
MEN multiple endocrine neoplasia
SINET small intestine
PanNET pancreatic neuroendocrine tumor
RECIST response evaluation criteria in solid tumors
CT computed tomography
US ultrasonography
MRI magnetic resonance imaging
PRRT peptide receptor radionuclide therapy
PPQ Predictor quotient
CI confidence interval
ISH in situ hybridization
CTC circulating tumor cells
EpNET extrapancreatic neuroendocrine tumor
ER endoscopic resection
HR hazard ratio
LAR long-acting release
mOS median overall survival
mPFS median progression-free survival
ORS objective response rate
PET positron emitting radionuclide
PFS progression-free survival
RR response rate
SPECT gamma emitting radionuclide
SSA somatostatin analogs
SSTR somatostatin receptor